Boosting Fosfomycin Efficacy Against Methicillin-Resistant Staphylococcus aureus Infections by Targeting Pyrimidine Metabolism

Jianya Luo; Qingyan Lv; Mengping He; Zhiqiang Wang; Yuan Liu

doi:10.1016/j.eng.2026.01.025

Engineering ›› :202601025 DOI: 10.1016/j.eng.2026.01.025

Research

research-article

Boosting Fosfomycin Efficacy Against Methicillin-Resistant Staphylococcus aureus Infections by Targeting Pyrimidine Metabolism

Author information +

History +

PDF

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) represents a significant global public health threat. Combination therapy, particularly the use of antibiotics in conjunction with non-antibiotic agents, has emerged as a promising strategy to address the growing crisis of antibiotic resistance. Fosfomycin (FOS), increasingly utilized in clinical practice for treating drug-resistant bacterial infections, exhibits limited efficacy as a monotherapy. Here, we find that 5-fluorouracil (5-FU), a Food and Drug Administration (FDA)-approved anticancer drug, effectively enhances the antibacterial activity of FOS against MRSA, including biofilm-embedded MRSA cells. Mechanistically, 5-FU targets cytidine triphosphate (CTP) synthase, a rate-limiting enzyme responsible for the adenosine triphosphate (ATP)-dependent conversion of uridine triphosphate (UTP) to CTP. Moreover, we demonstrate that the synergistic effect of 5-FU and FOS arises from the perturbation of pyrimidine metabolism, which induces membrane damage, dissipation of the proton motive force (PMF), enhanced ATP synthesis, and accumulation of reactive oxygen species, culminating in bacterial death. In both Galleria mellonella (G. mellonella) and murine infection models, the combination of 5-FU and FOS markedly improves survival and reduces bacterial burdens. Collectively, our work demonstrates the therapeutic potential of 5-FU combined with FOS for tackling MRSA infections and highlights the pivotal role of perturbing pyrimidine metabolism in restoring antibiotic susceptibility.

Keywords

Antibiotic adjuvant / 5-Fluorouracil / Fosfomycin / MRSA / Pyrimidine metabolism

Cite this article

Download citation ▾

Jianya Luo, Qingyan Lv, Mengping He, Zhiqiang Wang, Yuan Liu. Boosting Fosfomycin Efficacy Against Methicillin-Resistant Staphylococcus aureus Infections by Targeting Pyrimidine Metabolism. Engineering 202601025 DOI:10.1016/j.eng.2026.01.025

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Lakhundi S, Zhang K. Methicillin-resistant Staphylococcus aureus : molecular characterization, evolution, and epidemiology. Clin Microbiol Rev 2018; 31(4): e00020-118.

[2]	Adedeji-Olulana AF, Wacnik K, Lafage L, Pasquina-Lemonche L, Tinajero-Trejo M, Sutton JAF, et al. Two codependent routes lead to high-level MRSA. Science 2024; 386(6721):573-80.

[3]	Yang R, Hou E, Cheng W, Yan X, Zhang T, Li S, et al. Membrane-targeting neolignan-antimicrobial peptide mimic conjugates to combat methicillin-resistant Staphylococcus aureus (MRSA) infections. J Med Chem 2022; 65 (24):16879-92.

[4]	Rossolini GM, Arena F, Pecile P, Pollini S. Update on the antibiotic resistance crisis. Curr Opin Pharmacol 2014;18:56-60.

[5]	Simard F, Gauthier C, Legault J, Lavoie S, Mshvildadze V, Pichette A. Structure elucidation of anti-methicillin resistant Staphylococcus aureus (MRSA) flavonoids from balsam poplar buds. Bioorg Med Chem 2016; 24(18):4188-98.

[6]	Borg MA, Camilleri L. What is driving the epidemiology of methicillin-resistant Staphylococcus aureus infections in Europe? Microb Drug Resist 2021; 27 (7):889-94.

[7]	Bai AD, Lo CK, Komorowski AS, Suresh M, Guo K, Garg A, et al. Staphylococcus aureus bacteremia mortality across country income groups: a secondary analysis of a systematic review. Int J Infect Dis 2022;122:405-11.

[8]	Sun H, Zhang Q, Wang R, Wang H, Wong YT, Wang M, et al. Resensitizing carbapenem-and colistin-resistant bacteria to antibiotics using auranofin. Nat Commun 2020; 11(1):5263.

[9]	Wang C, Xia Y, Wang R, Li J, Chan CL, Kao RY, et al. Metallo-sideromycin as a dual functional complex for combating antimicrobial resistance. Nat Commun 2023; 14(1):5311.

[10]	Toumi M, Rémuzat C. Value added medicines: what value repurposed medicines might bring to society? J Mark Access Health Policy 2017; 5 (1):1264717.

[11]	Cacace E, Kim V, Varik V, Knopp M, Tietgen M, Brauer-Nikonow A, et al. Systematic analysis of drug combinations against Gram-positive bacteria. Nat Microbiol 2023; 8(11):2196-212.

[12]	Tyers M, Wright GD. Drug combinations: a strategy to extend the life of antibiotics in the 21st century. Nat Rev Microbiol 2019; 17(3):141-55.

[13]	Bollenbach T. Antimicrobial interactions: mechanisms and implications for drug discovery and resistance evolution. Curr Opin Microbiol 2015;27:1-9.

[14]	Theuretzbacher U, Van Bambeke F, Cantón R, Giske CG, Mouton JW, Nation RL, et al. Reviving old antibiotics. J Antimicrob Chemother 2015; 70(8):2177-81.

[15]	Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. Clin Microbiol Rev 2016; 29(2):321-47.

[16]	Kaye KS, Gales AC, Dubourg G. Old antibiotics for multidrug-resistant pathogens: from in vitro activity to clinical outcomes. Int J Antimicrob Agents 2017; 49(5):542-8.

[17]	Cohen SS, Flaks JG, Barner HD, Loeb MR, Lichtenstein J. The mode of action of 5-fluorouracil and its derivatives. Proc Natl Acad Sci USA 1958; 44(10):1004-12.

[18]	Kim W, Zhu W, Hendricks GL, Van Tyne D, Steele AD, Keohane CE, et al. A new class of synthetic retinoid antibiotics effective against bacterial persisters. Nature 2018; 556(7699):103-7.

[19]

Walz JM, Avelar RL, Longtine KJ, Carter KL, Mermel LA, Heard SO, et al. Anti-infective external coating of central venous catheters: a randomized, noninfer iority trial comparing 5-fluorouracil with chlorhexidine/silver sulfadiazine in preventing catheter colonization. Crit Care Med 2010; 38(11):2095-102.

[20]	Zuo J, Quan Y, Li J, Li Y, Song D, Li X, et al. Tackling antibiotic resistance: exploring 5-fluorouracil as a promising antimicrobial strategy for the treatment of Streptococcus suis infection. Animals 2024; 14(9):1286.

[21]	Gieringer JH, Wenz AF, Just HM, Daschner FD. Effect of 5-fluorouracil, mitoxantrone, methotrexate, and vincristine on the antibacterial activity of ceftriaxone, ceftazidime, cefotiam, piperacillin, and netilmicin. Chemotherapy 1986; 32(5):418-24.

[22]	Nyhlén A, Ljungberg B, Nilsson-Ehle I, Odenholt I. Bactericidal effect of combinations of antibiotic and antineoplastic agents against Staphylococcus aureus and Escherichia coli. Chemotherapy 2002; 48(2):71-7.

[23]	Hussain M, Collins C, Hastings JG, White PJ. Radiochemical assay to measure the biofilm produced by coagulase-negative staphylococci on solid surfaces and its use to quantitate the effects of various antibacterial compounds on the formation of the biofilm. J Med Microbiol 1992; 37(1):62-9.

[24]	Attila C, Ueda A, Wood TK. 5-Fluorouracil reduces biofilm formation in Escherichia coli K-12 through global regulator AriR as an antivirulence compound. Appl Microbiol Biotechnol 2009; 82(3):525-33.

[25]	Zhang M, Yang S, Liu Y, Zou Z, Zhang Y, Tian Y, et al. Anticancer agent 5-fluorouracil reverses meropenem resistance in carbapenem-resistant Gram-negative pathogens. Int J Antimicrob Agents 2024; 64(5):107337.

[26]	Liu Y, Jia Y, Yang K, Li R, Xiao X, Zhu K, et al. Metformin restores tetracyclines susceptibility against multidrug resistant bacteria. Adv Sci 2020; 7 (12):1902227.

[27]	Stokes JM, Yang K, Swanson K, Jin W, Cubillos-Ruiz A, Donghia NM, et al. A deep learning approach to antibiotic discovery. Cell 2020; 180(4):688-702.

[28]	Zhang S, Tang H, Wang Y, Nie B, Yang H, Yuan W, et al. Antibacterial and antibiofilm effects of flufenamic acid against methicillin-resistant Staphylococcus aureus. Pharmacol Res 2020;160:105067.

[29]	Le P, Kunold E, Macsics R, Rox K, Jennings MC, Ugur I, et al. Repurposing human kinase inhibitors to create an antibiotic active against drug-resistant Staphylococcus aureus, persisters and biofilms. Nat Chem 2020; 12(2):145-58.

[30]	de Breij A, Riool M, Kwakman PH, de Boer L, Cordfunke RA, Drijfhout JW, et al. Prevention of Staphylococcus aureus biomaterial-associated infections using a polymer-lipid coating containing the antimicrobial peptide OP-145. J Control Release 2016;222:1-8.

[31]	Silva ON, Torres MDT, Cao J, Alves ESF, Rodrigues LV, Resende JM, et al. Repurposing a peptide toxin from wasp venom into antiinfectives with dual antimicrobial and immunomodulatory properties. Proc Natl Acad Sci USA 2020; 117(43):26936-45.

[32]	Ling LL, Schneider T, Peoples AJ, Spoering AL, Engels I, Conlon BP, et al. A new antibiotic kills pathogens without detectable resistance. Nature 2015; 517 (7535):455-9.

[33]	Antipov D, Korobeynikov A, McLean JS, Pevzner PA. HybridSPAdes: an algorithm for hybrid assembly of short and long reads. Bioinformatics 2016; 32(7):1009-15.

[34]	Cai J, Shi J, Chen C, He M, Wang Z, Liu Y. Structural-activity relationship-inspired the discovery of saturated fatty acids as novel colistin enhancers. Adv Sci 2023; 10(29):e2302182.

[35]	Chen W, Zhang Y, Yeo WS, Bae T, Ji Q. Rapid and efficient genome editing in Staphylococcus aureus by using an engineered CRISPR/Cas9 system. J Am Chem Soc 2017; 139(10):3790-5.

[36]	Zhang S, Qu X, Jiao J, Tang H, Wang M, Wang Y, et al. Felodipine enhances aminoglycosides efficacy against implant infections caused by methicillin-resistant Staphylococcus aureus, persisters and biofilms. Bioact Mater 2022;14:272-89.

[37]	Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-DD C(T)) method. Methods 2001; 25 (4):402-8.

[38]	Liu Y, Shi J, Tong Z, Jia Y, Yang K, Wang Z. Potent broad-spectrum antibacterial activity of amphiphilic peptides against multidrug-resistant bacteria. Microorganisms 2020; 8(9):1398.

[39]	Heidelberger C, Chaudhuri NK, Danneberg P, Mooren D, Griesbach L, Duschinsky R, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957; 179(4561):663-6.

[40]	Mao C, Xiang Y, Liu X, Zheng Y, Yeung KWK, Cui Z, et al. Local photothermal/photodynamic synergistic therapy by disrupting bacterial membrane to accelerate reactive oxygen species permeation and protein leakage. ACS Appl Mater Interfaces 2019; 11(19):17902-14.

[41]	Jia Y, Yang B, Shi J, Fang D, Wang Z, Liu Y. Melatonin prevents conjugative transfer of plasmid-mediated antibiotic resistance genes by disrupting proton motive force. Pharmacol Res 2022;175:105978.

[42]	Zhang H, Chen Q, Xie J, Cong Z, Cao C, Zhang W, et al. Switching from membrane disrupting to membrane crossing, an effective strategy in designing antibacterial polypeptide. Sci Adv 2023; 9(4):eabn0771.

[43]	Kumar A, Boradia VM, Thakare R, Singh AK, Gani Z, Das S, et al. Repurposing ethyl bromopyruvate as a broad-spectrum antibacterial. J Antimicrob Chemother 2019; 74(4):912-20.

[44]	Yssel AEJ, Vanderleyden J, Steenackers HP. Repurposing of nucleoside-and nucleobase-derivative drugs as antibiotics and biofilm inhibitors. J Antimicrob Chemother 2017; 72(8):2156-70.

[45]	Fang J, Uchiumi T, Yagi M, Matsumoto S, Amamoto R, Takazaki S, et al. Dihydro-orotate dehydrogenase is physically associated with the respiratory complex and its loss leads to mitochondrial dysfunction. Biosci Rep 2013; 33 (2):e00021.

[46]	Farha MA, Verschoor CP, Bowdish D, Brown ED. Collapsing the proton motive force to identify synergistic combinations against Staphylococcus aureus. Chem Biol 2013; 20(9):1168-78.

[47]	Lobritz MA, Belenky P, Porter CB, Gutierrez A, Yang JH, Schwarz EG, et al. Antibiotic efficacy is linked to bacterial cellular respiration. Proc Natl Acad Sci USA 2015; 112(27):8173-80.

[48]	Liu Y, Yang K, Jia Y, Shi J, Tong Z, Wang Z. Thymine sensitizes Gram-negative pathogens to antibiotic killing. Front Microbiol 2021;12:622798.

[49]	Imlay JA. The molecular mechanisms and physiological consequences of oxidative stress: lessons from a model bacterium. Nat Rev Microbiol 2013; 11 (7):443-54.

[50]	Halasi M, Wang M, Chavan TS, Gaponenko V, Hay N, Gartel AL. ROS inhibitor N-acetyl-L-cysteine antagonizes the activity of proteasome inhibitors. Biochem J 2013; 454(2):201-8.

[51]	Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from the infectious diseases society of America. Clin Infect Dis 2009; 48(1):1-12.

[52]	Melander RJ, Melander C. The challenge of overcoming antibiotic resistance: an adjuvant approach? ACS Infect Dis 2017; 3(8):559-63.

[53]	Zhang S, Qu X, Tang H, Wang Y, Yang H, Yuan W, et al. Diclofenac resensitizes methicillin-resistant Staphylococcus aureus to b-lactams and prevents implant infections. Adv Sci 2021; 8(13):2100681.

[54]	Czaplewski L, Bax R, Clokie M, Dawson M, Fairhead H, Fischetti VA, et al. Alternatives to antibiotics—a pipeline portfolio review. Lancet Infect Dis 2016; 16(2):239-51.

[55]	Johnson BK, Abramovitch RB. Small molecules that sabotage bacterial virulence. Trends Pharmacol Sci 2017; 38(4):339-62.

[56]	Dickey SW, Cheung GYC, Otto M. Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. Nat Rev Drug Discov 2017; 16 (7):457-71.

[57]	DiGiandomenico A, Sellman BR. Antibacterial monoclonal antibodies: the next generation? Curr Opin Microbiol 2015;27:78-85.

[58]	Skeiky YA, Sadoff JC.Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 2006; 4(6):469-76.

[59]	Chi J, Li Y, Zhang N, Liu H, Chen Z, Li J, et al. Fosfomycin enhances the inhibition ability of linezolid against biofilms of vancomycin-resistant Enterococcus faecium in vitro. Infect Drug Resist 2023;16:7707-19.

[60]	Ribeiro ACDS, Chikhani YCDSA, Valiatti TB, Valêncio A, Kurihara MNL, Santos FF, et al. In vitro and in vivo synergism of fosfomycin in combination with meropenem or polymyxin B against KPC-2-producing Klebsiella pneumoniae clinical isolates. Antibiotics 2023; 12(2):237.

[61]	Yan J, Bassler BL. Surviving as a community: antibiotic tolerance and persistence in bacterial biofilms. Cell Host Microbe 2019; 26(1):15-21.

[62]	Defraine V, Fauvart M, Michiels J. Fighting bacterial persistence: current and emerging anti-persister strategies and therapeutics. Drug Resist Updat 2018;38:12-26.

[63]	Rao Y, Qin C, Savas AC, Liu Q, Feng S, Hou G, et al. Pyrimidine synthesis enzyme CTP synthetase 1 suppresses antiviral interferon induction by deamidating IRF3. Immunity 2025; 58(1):74-89.

[64]	Oe C, Hayashi H, Hirata K, Kawaji K, Hashima F, Sasano M, et al. Pyrimidine analogues as a new class of Gram-positive antibiotics, mainly targeting thymineless-death related proteins. ACS Infect Dis 2020; 6(6):1490-500.

[65]	Zheng YD, Zhong T, Wu H, Li N, Fang Z, Cao L, et al. Crizotinib shows antibacterial activity against Gram-positive bacteria by reducing ATP production and targeting the CTP synthase PyrG. Microbiol Spectr 2022; 10 (3):e0088422.